Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
By Human Services Department, Food, Health, Drug Administration · Nov 11, 2026, 11:00 PM CST
The Food and Drug Administration (FDA) is proposing to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket no
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisTechnical languageThe use of regulatory terminology conveys authority and precision, targeting a professional audience familiar with FDA device classifications.
Policy framingThe framing emphasizes safety and effectiveness, presenting the reclassification as a measured regulatory adjustment rather than a deregulation.
Context
AI analysisMissing context
The excerpt does not explain the rationale behind the reclassification, the expected impact on manufacturers, clinicians, or patients, nor does it provide details about the specific special controls that would be required.
Important context
Reclassification from class III to class II typically reduces regulatory burden while maintaining safety through special controls. Understanding the FDA’s justification and the specific controls is essential for assessing the significance of the change.
Opinion vs. reporting
AI analysisThe passage is purely factual reporting of a regulatory proposal; it contains no opinion or editorial commentary.